Current progress in dengue vaccines

Shu Wen Wan, Chiou Feng Lin, Shuying Wang, Yu Hung Chen, Trai Ming Yeh, Hsiao Sheng Liu, Robert Anderson, Yee Shin Lin

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

Original languageEnglish
Article number37
JournalJournal of Biomedical Science
Volume20
Issue number1
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Dengue Vaccines
Viruses
Severe Dengue
Attenuated Vaccines
Dengue
Vaccines
Dengue Virus
Virus Diseases
Inactivated Vaccines
Subunit Vaccines
DNA Vaccines
Autoimmunity
Thrombocytopenia
Blood Vessels
Animal Models
Clinical Trials
Hemorrhage
Safety
Animals
Antibodies

Keywords

  • Dengue
  • Immunopathogenesis
  • Vaccine

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Cell Biology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Wan, S. W., Lin, C. F., Wang, S., Chen, Y. H., Yeh, T. M., Liu, H. S., ... Lin, Y. S. (2013). Current progress in dengue vaccines. Journal of Biomedical Science, 20(1), [37]. https://doi.org/10.1186/1423-0127-20-37

Current progress in dengue vaccines. / Wan, Shu Wen; Lin, Chiou Feng; Wang, Shuying; Chen, Yu Hung; Yeh, Trai Ming; Liu, Hsiao Sheng; Anderson, Robert; Lin, Yee Shin.

In: Journal of Biomedical Science, Vol. 20, No. 1, 37, 2013.

Research output: Contribution to journalArticle

Wan, SW, Lin, CF, Wang, S, Chen, YH, Yeh, TM, Liu, HS, Anderson, R & Lin, YS 2013, 'Current progress in dengue vaccines', Journal of Biomedical Science, vol. 20, no. 1, 37. https://doi.org/10.1186/1423-0127-20-37
Wan, Shu Wen ; Lin, Chiou Feng ; Wang, Shuying ; Chen, Yu Hung ; Yeh, Trai Ming ; Liu, Hsiao Sheng ; Anderson, Robert ; Lin, Yee Shin. / Current progress in dengue vaccines. In: Journal of Biomedical Science. 2013 ; Vol. 20, No. 1.
@article{c86f269e639d440eb7134ef3ad42dc2f,
title = "Current progress in dengue vaccines",
abstract = "Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.",
keywords = "Dengue, Immunopathogenesis, Vaccine",
author = "Wan, {Shu Wen} and Lin, {Chiou Feng} and Shuying Wang and Chen, {Yu Hung} and Yeh, {Trai Ming} and Liu, {Hsiao Sheng} and Robert Anderson and Lin, {Yee Shin}",
year = "2013",
doi = "10.1186/1423-0127-20-37",
language = "English",
volume = "20",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Current progress in dengue vaccines

AU - Wan, Shu Wen

AU - Lin, Chiou Feng

AU - Wang, Shuying

AU - Chen, Yu Hung

AU - Yeh, Trai Ming

AU - Liu, Hsiao Sheng

AU - Anderson, Robert

AU - Lin, Yee Shin

PY - 2013

Y1 - 2013

N2 - Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

AB - Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

KW - Dengue

KW - Immunopathogenesis

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84878818110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878818110&partnerID=8YFLogxK

U2 - 10.1186/1423-0127-20-37

DO - 10.1186/1423-0127-20-37

M3 - Article

VL - 20

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 37

ER -